How to Determine the Dosing (in Different Populations/Tissues) - Dr. Capparelli

International Workshop on Monoclonal Antibodies for HIV, COVID-19, and Oncology 2021

Monoclonal Antibodies for Treatment in Hematologic Malignancies - Dr. Moskowitz

International Workshop on Monoclonal Antibodies for HIV, COVID-19, and Oncology 2021

Monoclonal Antibodies for Treatment in Autoimmune Diseases - Dr. Chan

International Workshop on Monoclonal Antibodies for HIV, COVID-19, and Oncology 2021

Monoclonal Antibodies for Prevention of HIV, COVID, and Ebola - Dr, Cohen

International Workshop on Monoclonal Antibodies for HIV, COVID-19, and Oncology 2021

Monoclonal Antibodies for Treatment in HIV - Dr. Caskey

International Workshop on Monoclonal Antibodies for HIV, COVID-19, and Oncology 2021

Monoclonal Antibodies for Treatment in COVID-19 - Prof. Ader

International Workshop on Monoclonal Antibodies for HIV, COVID-19, and Oncology 2021

Screening Technologies & Platforms - Dr. Robbiani

International Workshop on Monoclonal Antibodies for HIV, COVID-19, and Oncology 2021

Monoclonal Antibodies Against COVID-19: Targets, Development and Clinical Applications - Prof. Autran

International Workshop on Monoclonal Antibodies for HIV, COVID-19, and Oncology 2021

Historical Perspectives from Pasteur to Flexner: The Evolution of Serum to Monoclonal Antibody Therapy - Prof. Flexner

International Workshop on Monoclonal Antibodies for HIV, COVID-19, and Oncology 2021

Benefits of data collaboration – personalized tailoring regimens | Rada Savic, PharmD, PhD

International Workshop on Clinical Pharmacology of Tuberculosis Drugs 2017

A Cardiac Risk Algorithm to Predict the Probability of Drug-Induced Torsades de Pointes with Novel Anti-TB Agents | Alexander Berg, PharmD, PhD, FCP

International Workshop on Clinical Pharmacology of Tuberculosis Drugs 2017

Searching for a Universal Regimen for Tuberculosis Treatment with a Shorter Duration of Therapy | Khisi Mdluli, PhD

International Workshop on Clinical Pharmacology of Tuberculosis Drugs 2017

International Workshop on Clinical Pharmacology of Anticancer Drugs (ICPAD) 2019

New Designs for Early Clinical Trials of IO Drugs - Emiliano Calvo, Md, PhD

International Workshop on Clinical Pharmacology of Anticancer Drugs (ICPAD) 2019

Changes and Challenges in Early Phase Trial Endpoints - Ruth Plummer, MD

International Workshop on Clinical Pharmacology of Anticancer Drugs (ICPAD) 2019

Long Term Pemetrexed-based Cancer Treatment Leads to Nephrotoxicity - Nikki de Rouw

International Workshop on Clinical Pharmacology of Anticancer Drugs (ICPAD) 2019

Prediction of Capecitabine induced Severe Toxicity using Machine Learning Techniques - Maël Steunou

International Workshop on Clinical Pharmacology of Anticancer Drugs (ICPAD) 2019

The Long and Winding Road of the Clinical Introduction of a Biomarker - Jack Schalken, PhD

International Workshop on Clinical Pharmacology of Anticancer Drugs (ICPAD) 2019

The Use of Radiolabeled and Fluorescent Monoclonal Antibodies for Molecular Imaging in Oncology - Annelies Jorritsma-Smit, PharmD, PhD

International Workshop on Clinical Pharmacology of Anticancer Drugs (ICPAD) 2019

Epigenetic Regulation of OCTN1-mediated Cytarabine Transport in Acute Myeloid Leukemia - Jason Anderson

International Workshop on Clinical Pharmacology of Anticancer Drugs (ICPAD) 2019

Comprehensive Pan-Cancer Analysis of Somatic Mutations in Drug Transporters to Reveal Acquired and Intrinsic Drug Resistance in 3149 Metastatic Cancer Patients - Wesley van de Geer

International Workshop on Clinical Pharmacology of Anticancer Drugs (ICPAD) 2019

How System Pharmacology Can Facilitate Clinical Drug Development in Oncology - Piet van der Graaf, PharmD, PhD

International Workshop on Clinical Pharmacology of Anticancer Drugs (ICPAD) 2019

Impact of Immortal Time and Selection Bias on Exposure-response Modelling - Mats Karlsson, PhD, FCP, FISoP

International Workshop on Clinical Pharmacology of Anticancer Drugs (ICPAD) 2019

Clinical Pharmacology Strategy for Development and Labelling of New Medicine in the Era of Targeted Therapy and Accelerated Approvals in Oncology - Berges & Schalkwijk

International Workshop on Clinical Pharmacology of Anticancer Drugs (ICPAD) 2019